Arama Sonuçları - M.-H. Ryu

  • Gösterilen 1 - 11 sonuçlar arası kayıtlar. 11
Sonuçları Daraltın
  1. 1
    Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

    Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum Yazar: Dok Hyun Yoon, M.-H. Ryu, Y S Park, Heon‐Jin Lee, C Lee, B-Y. Ryoo, Jia-Lin Lee, H.-M. Chang, T W Kim, Y-K. Kang

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

    Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib Yazar: Y-K. Kang, Changhoon Yoo, B-Y. Ryoo, J J Lee, Eugene Tan, Inkeun Park, J H Park, Yoon Ji Choi, Jungmin Jo, J.-S. Ryu, M.H. Ryu

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

    Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in... Yazar: Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel, J.C. Soria, Josep Tabernero

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation

    Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation Yazar: Dok Hyun Yoon, Baek‐Yeol Ryoo, M.-H. Ryu, S.-G. Lee, Sun Moon Hwang, Dong Jin Suh, H.-C. Lee, Tae Won Kim, Cheol Soo Ahn, K.-H. Kim, Deok‐Bog Moon, Y.-K. Kang

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

    1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in... Yazar: Kensei Yamaguchi, Y-J. Bang, Satoru Iwasa, Naotoshi Sugimoto, M.H. Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, J. Lee, Kaku Saito, Yoshiaki Kawaguchi, Takahiro Kamio, A. Kojima, M. Sugihara, Kohei Shitara

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

    A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer Yazar: Jia-Lin Lee, Y-K. Kang, Hye Jin Kang, KH Lee, Dae Young Zang, B-Y. Ryoo, J G Kim, S R Park, Wonseok Kang, D.B. Shin, M.-H. Ryu, Heung-Moon Chang, Tae‐Won Kim, Jin Ho Baek, Young Joo Min

    Baskı/Yayın Bilgisi 2008
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Effects of chemotherapy( Anthracyclin, Cyclophosphamide following docetaxel regimen) on sleep, anxiety, depression and quality of life in patients with breast cancer

    Effects of chemotherapy( Anthracyclin, Cyclophosphamide following docetaxel regimen) on sleep, anxiety, depression and quality of life in patients with breast cancer Yazar: Sang-Yhun Ju, Youn Joo Jung, Seungju Lee, Seok Kyeong Kang, M.-H. Ryu, Jee Yeon Kim, Kyung Jin Nam, K. Lee, Ji Hyeon Joo, Youngkyung Jeon, Jae Joon Kim, Ji Hoon Kim, Su Bong Nam, Mi Sook Yun, Hyun Yul Kim

    Baskı/Yayın Bilgisi 2025
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

    Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma Yazar: Kohei Shitara, Mustafa Özgüroğlu, Y.-J. Bang, Maria Di Bartolomeo, Mario Mandalà, M.-H. Ryu, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eric Van Cutsem, Julie Kobie, Rǎzvan Cristescu, Deepti Aurora-Garg, Lu Jia, C.-S. Shih, David E. Adelberg, Z. Alexander Cao, Charles S. Fuchs

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)

    Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, fo... Yazar: Yoon‐Koo Kang, Jeong Hwan Yook, Y.-K. Park, Young‐Woo Kim, J. Kim, M.-H. Ryu, Sun Young Rha, Ik‐Joo Chung, I.-H. Kim, Sang Cheul Oh, Chung-Sik Yoo, Jin-Hyuk Choi, Dae Young Zang, Gil-joong Kim, Y. Lee, Sung Hoon Noh

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

    LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTI... Yazar: Narikazu Boku, M.-H. Ryu, D-Y. Oh, Sang Cheul Oh, Hyun Cheol Chung, Kyung-Woo Lee, Takeshi Omori, Kohei Shitara, S. Sakuramoto, Ick‐Joong Chung, Kensei Yamaguchi, Katsuhiko Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jin‐Shing Chen, L-Y. Bai, L-T. Chen, Y-K. Kang

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

    VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-8... Yazar: Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber, Yibing Bai, M.H. Ryu, J. Lee, F. Rivera, G.V. Alves, Marcelo Garrido, K-K. Shiu, M. González Fernández, J. Li, M. Lowery, T. Çil, F.J.S.M. Cruz, S. Qin, L. Yin, S. Bordia, P. Bhagia, D-Y. Oh

    Baskı/Yayın Bilgisi 2023
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: